A substudy of the Beat AML Master Trial tested the combination of a Syk inhibitor, entospletinib, and 10-day decitabine as a phase II study, which also demonstrated a disappointingly low CR rate of 13.3% and short median OS of 6.5 months [70] (Table 1). The gene discussed is SYK; the disease is acute myeloid leukemia.